Cargando…

An algorithm using clinical data to predict the optimal individual glucocorticoid dosage to treat multiple sclerosis relapses

BACKGROUND: Glucocorticoid (GC) pulse therapy is used for multiple sclerosis (MS) relapse treatment; however, GC resistance is a common problem. Considering that GC dosing is individual with several response-influencing factors, establishing a predictive model, which supports clinicians to estimate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gili-Kovács, Judit, Hoepner, Robert, Salmen, Anke, Bagnoud, Maud, Gold, Ralf, Chan, Andrew, Briner, Myriam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216377/ https://www.ncbi.nlm.nih.gov/pubmed/34211583 http://dx.doi.org/10.1177/17562864211020074

Ejemplares similares

Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis
por: Hoepner, Robert, et al.
Publicado: (2019)

Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age
por: Briner, Myriam, et al.
Publicado: (2019)

c-Jun N-Terminal Kinase as a Therapeutic Target in Experimental Autoimmune Encephalomyelitis
por: Bagnoud, Maud, et al.
Publicado: (2020)

In Vivo and In Vitro Evidence for an Interplay between the Glucocorticoid Receptor and the Vitamin D Receptor Signaling
por: Bagnoud, Maud, et al.
Publicado: (2023)

Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course
por: Zoehner, Greta, et al.
Publicado: (2019)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
por: Hoepner, Robert, et al.
Publicado: (2014)

A Brief Review of the Effects of Vitamin D on Multiple Sclerosis
por: Miclea, Andrei, et al.
Publicado: (2020)

Dimethyl fumarate vs fingolimod following different pretreatments: A retrospective study
por: Diem, Lara, et al.
Publicado: (2020)

Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations
por: Remlinger, Jana, et al.
Publicado: (2023)

Socioeconomic and Regional Disparities in Industry-Sponsored Clinical Trials in Multiple Sclerosis
por: Marti, Stefanie, et al.
Publicado: (2023)

Age‐dependent variation of female preponderance across different phenotypes of multiple sclerosis: A retrospective cross‐sectional study
por: Miclea, Andrei, et al.
Publicado: (2018)

Pathological cerebrospinal fluid protein concentration and albumin quotient at relapse predicts short-term disability progression in multiple sclerosis: a retrospective single center observational study
por: Diem, Lara, et al.
Publicado: (2020)

Vaccine Hesitancy in Patients With Multiple Sclerosis: Preparing for the SARS-CoV-2 Vaccination Challenge
por: Diem, Lara, et al.
Publicado: (2021)

Application of the “risk of ambulatory disability” (RoAD) score in a “real‐world” single‐center multiple sclerosis cohort
por: Pistor, Maximilian, et al.
Publicado: (2022)

Is COVID‐19 severity associated with reduction in T lymphocytes in anti‐CD20‐treated people with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?
por: Hoepner, Robert, et al.
Publicado: (2022)

Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System
por: Pistor, Maximilian, et al.
Publicado: (2022)

Predicting conversion to multiple sclerosis in patients with radiologically isolated syndrome: a retrospective study
por: Chaloulos-Iakovidis, Panagiotis, et al.
Publicado: (2021)

The impact of immunotherapies on COVID-19 case fatality rates during the US vaccination campaign: a multidisciplinary open data analysis using FDA Adverse Event Reporting System and Our World in Data
por: Salmen, Anke, et al.
Publicado: (2023)

Multiple sclerosis as a model to investigate SARS‐CoV‐2 effect on brain atrophy
por: Rebsamen, Michael, et al.
Publicado: (2022)

Prediction of conversion to multiple sclerosis using the 2017 McDonald and 2016 MAGNIMS criteria in patients with clinically isolated syndrome: a retrospective single-centre study
por: Miclea, Andrei, et al.
Publicado: (2019)

Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG–Associated Experimental Autoimmune Encephalomyelitis
por: Remlinger, Jana, et al.
Publicado: (2022)

Incidence and mitigation of gastrointestinal events in patients with relapsing–remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE)
por: Gold, Ralf, et al.
Publicado: (2018)

Evaluation of diagnostic criteria and red flags of myelin oligodendrocyte glycoprotein encephalomyelitis in a clinical routine cohort
por: Veselaj, Krenar, et al.
Publicado: (2020)

Reliable brain morphometry from contrast‐enhanced T1w‐MRI in patients with multiple sclerosis
por: Rebsamen, Michael, et al.
Publicado: (2022)

Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients
por: Hammer, Helly, et al.
Publicado: (2022)

Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA’s Adverse Event Reporting System
por: Pistor, Maximilian, et al.
Publicado: (2021)

An Algorithm for Individual Dosage in Cadmium–Zinc–Telluride SPECT-Gated Radionuclide Angiography
por: Hansen, Maria Normand, et al.
Publicado: (2021)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Metabolic profiles by (1)H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML)
por: Schneider, Ruth, et al.
Publicado: (2017)

Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis
por: Thiele née Schrewe, Lisa, et al.
Publicado: (2020)

Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study
por: Rejdak, Konrad, et al.
Publicado: (2021)

Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis
por: Cagol, Alessandro, et al.
Publicado: (2022)

No optical coherence tomography changes in premanifest Huntington's disease mutation carriers far from disease onset
por: Schmid, Rahel Dominique, et al.
Publicado: (2022)

Feelings of loneliness, COVID-19-specific-health anxiety and depressive symptoms during the first COVID-19 wave in Swiss persons with multiple sclerosis
por: Hoepner, Robert, et al.
Publicado: (2022)

Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)
por: Gold, Ralf, et al.
Publicado: (2015)

Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy
por: Salmen, A., et al.
Publicado: (2016)

Thalamic–hippocampal–prefrontal disruption in relapsing–remitting multiple sclerosis
por: Kern, Kyle C., et al.
Publicado: (2014)

Glucocorticoid receptor mutations and clinical sensitivity to glucocorticoid in Chinese multiple sclerosis patients
por: Song, Tian, et al.
Publicado: (2020)

Adrenal Insufficiency under Standard Dosage of Glucocorticoid Replacement after Unilateral Adrenalectomy for Cushing's Syndrome
por: Fujii, Kentaro, et al.
Publicado: (2016)

High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
por: Freeman, Léorah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rfupr8a7bmtadspmpjk6ihqu1k